Xia L, Zhang K, Tang Y, Zhang G, et al. Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. J Clin Oncol 2025 Jun 25:JCO2402495. doi: 10.1200/JCO-24-02495.
PMID: 40561369